You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨無懼美藥品關税威脅,港股藥品股大升,恒瑞醫藥升超7%創上市新高
港股藥品股集體拉昇,其中,恒瑞醫藥升7.5%創上市新高,德琪醫藥、綠葉製藥升近6%,中國生物製藥、康哲藥業、翰森製藥、石藥集團、開拓藥業等跟升。消息上,美國總統特朗普週二在內閣會議期間表示,更多貿易協定即將出台,擬對進口銅加徵50%關税,藥品關税可能高達200%。有分析指出,藥品是高度敏感的民生領域,大幅加徵關税可能導致藥價飆升,引發公眾強烈反對。市場可能認為此類政策更可能是談判籌碼,實際執行概率低。個股方面,恒瑞醫藥公佈,子公司廣東恒瑞醫藥收到國家藥監局核准簽發關於SHR-2173注射液的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗;基石藥業-B與Istituto Gentili就舒格利單抗在西歐和英國達成獨家戰略合作;先聲藥業樂德奇拜單抗新藥上市申請獲國家藥監局受理。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account